Albiflorin suppresses breast cancer via the HINT2/NLRP3 signaling pathway.
Aliflorin suppresses BC progression by inhibiting the HINT2/NLRP3 signaling pathway, suggesting HINT2 is a viable biomarker and Al a promising therapeutic agent for BC treatment.